ERBB2 and pulmonary arterial hypertension: This case highlights the importance of considering pulmonary hypertension as a potential adverse event in patients on trastuzumab, particularly those with pulmonary metastases.<h4>Conclusion</h4>Clinicians should be aware of pulmonary complications in patients receiving HER2-targeted therapies, even when left ventricular function is preserved.